Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Insulin Peglispro vs Glargine on Lispro Dose Response in T1DM
NCT02152384Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Jun 2014
- Primary completion
- Dec 2014
- Modality
- Polymer-based Nanoparticles, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of insulin peglispro in type 1 diabetes mellitus (T1D) (2 arms), sponsored by Eli Lilly and Company. Primary endpoint: Plasma Glucose Area Under the Concentration Curve Zero Through 5 Hours Above Pre Meal Baseline for Insulin Lispro. Started Jun 2014; status: completed.
02
Drugs
insulin peglispro
03
Conditions
type 1 diabetes mellitus (T1D)
Beyond the preview
Go deeper on NCT02152384.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02152384.